Validating the translational potential of BTZ in Onc-p53 NSCLC, combinations of BTZ with carboplatin or the BH3-mimetic navitoclax were synergistically cytotoxic in vitro and effectively limited the growth of mutant p53–expressing NSCLC xenografts in vivo. The gene discussed is CASC3; the disease is non-small cell lung carcinoma.